SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a...
Cellectis Competitors or Alternatives
Cellectis's top competitors include Kite Pharma, CRISPR and Fate Therapeutics.
Cellectis VS Kite Pharma
Kite Pharma is Cellectis's top competitor. Kite Pharma was founded in 2009 in Santa Monica, California. Kite Pharma competes in the Biotechnology field. Kite Pharma generates $32.9M more revenue than Cellectis.
Cellectis VS CRISPR
CRISPR is perceived as one of Cellectis's biggest rivals. CRISPR's headquarters is in Zug, Zug, and was founded in 2013. Like Cellectis, CRISPR also competes in the Biotechnology industry. CRISPR generates 307% of Cellectis's revenue.
Cellectis VS Fate Therapeutics
Fate Therapeutics is one of Cellectis's top competitors. Fate Therapeutics is a Public company that was founded in San Diego, California in 2007. Like Cellectis, Fate Therapeutics also competes in the Biotechnology field. Fate Therapeutics has 329 more employees vs. Cellectis.
Looking for similar companies to Cellectis?
Similar Companies
Pharmaceuticals companies in Paris
See 113 companies
Pharmaceuticals companies in Île-de-FranceSee 164 companies
Biotechnology companies in ParisSee 157 companies
Biotechnology companies in Île-de-FranceSee 214 companies
Pharmaceuticals & Biotechnology companies in ParisSee 256 companies
Pharmaceuticals & Biotechnology companies in Île-de-FranceSee 372 companies
Pharmaceuticals companies in FranceSee 569 companies
Companies in Paris with employees in 100-250 rangeSee 583 companies
Companies in Île-de-France with employees in 100-250 rangeSee 757 companies
Trending News for Cellectis and Cellectis's Competitors
Novartis plans to acquire Regulus Therapeutics for $7.00 per share in cash, or $800 million, the microRNA specialist said Wednesday. This is more than ...
NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) announced the FDA has approved IMAAVY, a human FcRn-blocking monoclonal antibody, for the treatment o...
In This Article: Regeneron Pharmaceuticals, Inc. REGN reported first-quarter 2025 adjusted earnings per share (EPS) of $8.22, which missed the Zacks Co...
Volume growth of AMGN's key drugs like Evenity, Repatha and Kyprolis is expected to have been partially offset by biosimilar/generic competition for ma...
Novartis AG NVS reported first-quarter 2025 adjusted earnings per share of $2.28, beating the street view of $2.10 . Quarterly sales of $13.23 billion ...
Early findings from Johnson & Johnson's Phase IIb SunRISe-1 trial show the promise of TAR-200 in patients with Bacillus Calmette-Guérin-unresponsive, h...
More than 35,000 new cases of the blood cancer are diagnosed in Europe every year...
Lung Cancer Diagnostic And Screening Market is estimated to be valued at USD 2,980.8 Mn in 2025 and is expected to reach USD 5,845.8 Mn in 2032, exhibi...
Novartis raised its 2025 outlook after its core operating profit rose 23% on year, boosted by strong demand for its key drugs....
Frequently Asked Questions about Cellectis
Who are Cellectis's top competitors?
Cellectis's top 3 competitors are Kite Pharma, CRISPR, Fate Therapeutics.Who is similar to Cellectis?
Kite Pharma is the most similar to Cellectis. CRISPR and Fate Therapeutics are also similar to Cellectis.
Are Cellectis and Kite Pharma competitors?
Yes, Kite Pharma is one of Cellectis’s top competitors.